Accelerate data to discovery with large-scale proteomics
Biomarker identification has served as a bedrock to accelerate all aspects of drug discovery, from preclinical research, through clinical development and enabling approval by regulatory agencies. The development of novel strategies for mid- to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, Azenta Life Sciences, formerly GENEWIZ, has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts. In this tech note, discover the science behind this assay and how its optimal approach makes it easier to incorporate protein biomarker discovery into your preclinical and clinical research.
What you’ll learn:
- Discover the applications for high-plex proteomics
- The wide range of capabilities of multiplexed and high-plex Olink Explore Panels
- The results of Azenta’s supplementary study on Olink Explore 3072 Assay to characterize test performance
Complete the form to download the tech note!